Literature DB >> 16822368

Daptomycin for infective endocarditis.

Donald Levine.   

Abstract

Entities:  

Year:  2006        PMID： 16822368     DOI： 10.1007/s11908-006-0069-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  9 in total

1.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

3.  Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.

Authors:  O Korzeniowski; M A Sande
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

4.  Staphylococcus aureus endocarditis: a consequence of medical progress.

Authors:  Vance G Fowler; Jose M Miro; Bruno Hoen; Christopher H Cabell; Elias Abrutyn; Ethan Rubinstein; G Ralph Corey; Denis Spelman; Suzanne F Bradley; Bruno Barsic; Paul A Pappas; Kevin J Anstrom; Dannah Wray; Claudio Q Fortes; Ignasi Anguera; Eugene Athan; Philip Jones; Jan T M van der Meer; Tom S J Elliott; Donald P Levine; Arnold S Bayer
Journal:  JAMA       Date:  2005-06-22       Impact factor: 56.272

5.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside.

Authors:  M J Rybak; L M Albrecht; S C Boike; P H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

6.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  D P Levine; B S Fromm; B R Reddy
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

7.  Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.

Authors:  A W Heldman; T V Hartert; S C Ray; E G Daoud; T E Kowalski; V J Pompili; S D Sisson; W C Tidmore; K A vom Eigen; S N Goodman; P S Lietman; B G Petty; C Flexner
Journal:  Am J Med       Date:  1996-07       Impact factor: 4.965

8.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

9.  Clinafloxacin for the treatment of bacterial endocarditis.

Authors:  Donald P Levine; H Preston Holley; Irene Eiseman; Paul Willcox; Kenneth Tack
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.